Alnylam, PBL sign licensing agreement for Baulcombe & Hamilton RNAi patent
Alnylam has received world-wide, non-exclusive license to the Baulcombe patent from PBL for use in the field of human therapeutics. Both the companies have kept the financial terms
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.